Mr. Cable represents as outside general counsel a number of private and public companies, where he counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters. Representative M&A transactions include the sale of Onyx Pharmaceuticals to Amgen ($10.4 billion), the sale of Eloqua to Oracle ($1 billion), the majority sale of Foundation Medicine to Roche ($1 billion), the sale of Idenix to Merck ($3.8 billion), the sale of Pharmacyclics to AbbVie ($21 billion), the sale of Xoom to PayPal ($1 billion), the private company sale of Stemcentrix to Abbvie ($5.8 billion), the sale of Opower to Oracle ($600 million), the acquisition of NXP by Qualcomm ($47 billion), the acquisitions of Euticals ($358 million – Italy) and Gadea ($174 million – Spain) by AMRI, the acquisition of Auspex by Teva Pharmaceuticals ($3.5 billion), the private company acquisition of Cord Blood Registry by AMAG Pharmaceuticals ($700 million), the sale of Neustar to Golden Gate ($2.9 billion), the sale of Lionbridge to HIG ($400 million), the sale of AMRI to Carlisle and GTCR ($1.9 billion) and the sale of PAREXEL to Pamplona ($5 billion). In the course of his career, Mr. Cable has negotiated and executed over 300 M&A transactions. Mr. Cable also represents public companies in connection with highly confidential “activist” matters, including the successful negotiation of "Cooperation" Agreements with Elliot Management on behalf of Cognizant and Citrix.
Mr. Cable serves regularly as counsel in IPOs (most recently representing J.P. Morgan in the cross-border IPO of Trivago), follow-on offerings and convertible debt transactions (including the $1.5 billion convertible debt issuance by Citrix and multiple convertible debt issuances by AMAG). He has recently represented J.P. Morgan, Morgan Stanley, Citibank and Centerview Partners in M&A and Corporate Finance transactions.
Mr. Cable also represents a number of private venture backed life sciences companies in governance, capital formation and collaboration transactions (including Moderna, Rubius, Yumanity and Ohana).
Mr. Cable serves as a member of the President's Leadership Council at Dartmouth College and as chairman emeritus of the Buckingham Browne & Nichols School. He has also served for more than a decade as a member of the Board of Fellows of Harvard Medical School. Mr. Cable leads the firm’s Pro Bono efforts on behalf of CampHarbor View, a summer enrichment program for Boston’s youth.